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Radical cure ofPlasmodium vivax infection applies blood schizontocidal therapy against the acute attack and hypnozoitocidal therapy
against later relapse. Chloroquine andprimaquine have been used for 60 years in thismanner. Resistance to chloroquine by the para-
site now requires partnering other blood schizontocideswith primaquine.However, the safety and efficacy of primaquine against re-
lapsewhen combinedwith other drugs have not been demonstrated. This randomized, open-label, and relapse-controlled trial esti-
mated the efficacy of primaquine against relapsewhen administeredwith quinine or dihydroartemisinin-piperaquine for treatment of
the acute infection. Among 650 soldierswhohad returned to theirmalaria-free base in Java, Indonesia, after 12months inmalarious
Papua, Indonesia, 143with acuteP. vivaxmalaria were eligible for study. One hundred sixteen enrolled subjects were randomized to
these treatments: artesunate (200-mgdose followed by 100mg/day for 6 days), quinine (1.8 g/day for 7 days) plus concurrent prima-
quine (30mg/day for 14 days), or dihydroartemisinin (120mg) plus piperaquine (960mg) daily for 3 days followed 25 days later by
primaquine (30mg/day for 14 days). Follow-upwas for 12months.One hundred thirteen subjectswere analyzable. Relapse occurred
in 32 of 41 (78%) subjects administered artesunate alone (2.71 attacks/person-year), 7 of 36 (19%) administered quinine plus prima-
quine (0.23 attack/person-year), and 2 of 36 (6%) administered dihydroartemisinin-piperaquine plus primaquine (0.06 attack/person-
year). The efficacy of primaquine against relapsewas 92% (95%confidence interval [CI] 81% to 96%) for quinine plus primaquine
and 98% (95%CI 91% to 99%) for dihydroartemisinin-piperaquine plus primaquine. Antirelapse therapywith primaquine begun a
month after treatment of the acute attackwith dihydroartemisinin-piperaquine proved safe andhighly efficacious against relapse byP.
vivax acquired in Papua, Indonesia.
Malaria caused by Plasmodium vivax threatens severe illness intravelers and the several billion people living at risk in zones
of endemicity (1–4). Despite the long-standing dogma of benign
identity for this parasite, it is pernicious and often provokes life-
threatening illness (5). Unlike the other important cause of ma-
laria, Plasmodium falciparum, this parasite places dormant forms
in the liver (hypnozoites) that cause repeated attacks called re-
lapses (6). The only licensed therapy against relapse is primaquine
(PQ) used in combination with chloroquine (CQ) for the primary
attack, together called radical cure. Worsening CQ resistance
threatens this 60-year-old treatment (7), and PQ efficacy against
relapse has only rarely been estimated since its development in
experimental challenge of American prisoner volunteers. The fail-
ing efficacy of CQ and the uncertain efficacy of PQ raise doubts
regarding successful chemotherapeutic management of this dan-
gerous infection.
Emerging CQ-resistant P. vivax compels consideration of di-
hydroartemisinin (DHA) plus piperaquine (PP) as a blood schi-
zontocide with PQ (8). Although good evidence shows the safety
and efficacy of DHA-PP against acute vivax malaria (9, 10), no
evidence yet demonstrates the safety and efficacy of PQ against
relapse when partnered with DHA-PP. This is a critical gap be-
cause PQ efficacy against relapse depends on an appropriate com-
panion blood schizontocide: PQ administered following rather
than concurrently with quinine (QN) failed to prevent relapse of
the Chesson strain of P. vivax (11). These findings and others
indicate that replacing CQ in radical cure requires assessment of
the safety and efficacy of PQ against relapse when partnered with
each new blood schizontocidal therapy (12, 13).
Hypnozoites impose analytical ambiguities in estimating PQ
efficacy. Recurrent parasitemia following primary attack may
originate from failed therapy against asexual blood stages (recru-
descence), biting infectious anopheline mosquitoes (reinfection),
or hypnozoites (relapse). Parasitemia arising from relapse may be
genetically homologous, like recrudescence, or heterologous, like
reinfection (14). Discriminating these events using molecular
technologies is thus not yet possible, and this imposes limitations
in estimating PQ efficacy against relapse. Experimental challenge
in zones of nonendemicity largely solves this problem but imposes
logistical, fiscal, and ethical burdens. Recruitment of naturally in-
fected travelers who have returned to areas of nonendemicity (and
given effective blood schizontocidal therapy) can be used to rule
out reinfection and recrudescence, and recurrent parasitemias
could arise only from activated hypnozoites.
Variability in the timing and risk of relapse imposes another
analytical problem. The risk of relapse without PQ therapy ranges
from about 10% to 90%, and the first relapse may occur at anytime
between 3 and 52 weeks (15). Thus, a 10% relapse rate following
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PQ may represent 0% to 90% efficacy, depending on natural re-
lapse behaviors (16). Reliably estimating PQ efficacy thus requires
knowing the natural timing and risk of relapse, and a relapse con-
trol arm, i.e., subjects receiving no PQ, achieves this (17, 18).
The current study leveraged heavily exposed travelers who had
returned to an area of nonendemicity, together with a relapse
control arm, to derive relatively unambiguous estimates of PQ
efficacy. After a year of duty in malarious Papua, Indonesia, Indo-
nesian soldiers with vivax malaria were randomized to radical cure
with DHA-PP or QN and PQ or treatment with artesunate (AS)
without PQ and followed for 12 months in an area free from risk of
reinfection at their base in Java, Indonesia. The QN treatment arm
essentially served as a surrogate CQ arm in terms of a proven
partner drug with PQ, i.e., a positive control for PQ efficacy
against relapse. Prevalent CQ-resistant P. vivax parasites where
these infections were acquired (7) precluded a CQ treatment arm
in this study. The study thus aimed principally at estimating the
efficacy of PQ when partnered with DHA-PP.
MATERIALS AND METHODS
Study design and oversight. This randomized, open-label, relapse-con-
trolled trial estimated PQ efficacy against relapse when partnered with QN
or DHA-PP. Patients randomized to relapse control received AS. Subjects
were followed until they had recurrent P. vivax or for 12 months. Prior to
recruitment, the research team undertook structured seminars aimed at
familiarizing soldiers and commanders with informed consent to partic-
ipate in medical research. Institutional ethics review boards of the Faculty
of Medicine, University of Indonesia, Jakarta, Indonesia, and the Nuffield
Department of Medicine, University of Oxford, Oxford, United King-
dom, reviewed and approved a protocol detailing the conduct of this
work. Authorized food and drug regulators for Indonesia (Badan Penga-
was Obat dan Makanan, Jakarta, Indonesia) reviewed, approved, and later
audited the trial in progress. An appointed data safety monitoring board
(DSMB) reviewed periodic summaries of adverse events and reports of
severe adverse events within several days of their occurrence. The trial was
registered with ISRCTN as trial no. 38290380 after commencement of
enrollment as a consequence of administrative error. The editor of this
journal reviewed the approved protocol for this trial as a condition of
acceptance of the manuscript for publication.
Study sites and subjects.The Indonesian army base at Lumajang, East
Java, Indonesia, served as the study site. The surrounding district of
Lumajang (1,053,000 residents) had an average population density of 588/
km2. Twenty-five health care delivery centers and five hospitals performed
9,015 blood film examinations for malaria in 2010, with none being pos-
itive. During 2011, authorities reported 10 cases of malaria, all classified as
imported. A mass blood survey of 1,155 schoolchildren conducted in
February 2012 in areas considered to be at a relatively high risk of malaria
transmission uncovered no cases. The subjects of the current study were
thus considered free of risk of reinfection during the posttreatment period
of follow-up (19, 20).
Six hundred fifty soldiers based at Lumajang deployed for duties in
northeastern Papua in October 2009. Previous studies of soldiers in the
same area of that deployment showed P. vivax infection rates of 2/person-
year (21, 22). The soldiers departed Papua on 1 November 2010, and on 8
November 2010 they disembarked from a ship at Surabaya, East Java.
They remained at port for several days for routine health screening prior
to their repatriation to Lumajang. After the soldiers resettled at their base
and the study was explained to troops and commanders, screening by
mass blood surveys commenced on 30 November 2010 and continued on
a rolling basis through April 2011, when enrollment closed. The research
team operated an all-hours clinic and encouraged soldiers with illness to
visit at any time.
Soldiers positive for vivax malaria by microscopy were invited for
counseling, to provide informed consent, and clinical assessment. Labo-
ratory screening of venous blood included a complete blood count
(Coulter Ac-T diff analyzer; Beckman Coulter, Brea, CA), analysis of liver
and renal function (BS-120 chemical analyzer; Mindray, Guangdong,
China), electrolyte concentrations (Ilyte electrolyte analyzer; Medica Cor-
poration, MA), and glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency (NADPH qualitative spot test; kit 203A; Trinity Biotech, Wicklow,
Ireland). Physical examination included an electrocardiogram (BTL-08;
BTL Industries Inc., MA) that used 12 leads with a paper speed of 50 mm/s
and that was calibrated to 10 mm/mV. Exclusion criteria included refusal
to provide informed consent, any condition requiring hospitalization, a
history or evidence of any disorder incompatible with subject safety, def-
inite plans for absence from the site within 28 days, G6PD deficiency, liver
transferase levels2.5-fold above the upper limit of normal, a Fridericia-
corrected QT interval of450 ms, or anemia (hemoglobin level,8 g/dl).
Drug therapy. A randomized list of study numbers that were block
allocated was generated by varying the blocking number at random (23).
An envelope revealing the assigned therapy was opened after informed
consent. Assignments were as follows: for AS, 200 mg AS (Arsuamoon; a
50-mg artesunate tablet packaged with an amodiaquine hydrochloride
tablet [discarded]; Guilin Pharmaceuticals Co. Ltd., Shanghai, China) was
administered, followed by a daily dose of 100 mg daily for 6 days. For QN
plus PQ (QNPQ), 200-mg quinine base tablets (Q; Kimia Pharma,
Bandung, Indonesia) were administered 3 times/day for 7 days at 10
mg/kg of body weight per dose and were given concurrently with a single
daily dose of two tablets each containing 15 mg primaquine base (Mala-
free; Shin Poon Pharmaceuticals, Seoul, South Korea) for 14 days. Sub-
jects weighing70 kg received a 45-mg PQ daily dose. For DHA-PP plus
PQ (DHA-PPPQ), a single daily dose of 3 tablets, each containing 40 mg
dihydroartemisinin base and 320 mg piperaquine base (Eurartesim;
Sigma Tau, Italy), was administered for 3 days. Primaquine was adminis-
tered precisely as detailed above, except that dosing commenced on day 28
following enrollment.
The WHO recommends a daily adult primaquine dose of 15 mg, 22.5
mg, or 30 mg for 14 days, depending on geographic origin; i.e., in South-
east Asia or Oceania, the higher dose is required (24). This study applied
the 30-mg daily dose or a 45-mg daily dose to subjects weighting70 kg
(25). PQ dosing commenced on day 28 after starting DHA-PP because the
safety of concurrent administration remains unknown.
Clinical procedures. A clinical team member witnessed and signature
affirmed all doses, as did the subject. Subjects were offered and encour-
aged to consume a nonfatty, carbohydrate snack prior to consuming med-
ication. Subjects were observed for 1 h, and emesis prompted repeated
dosing. On days 3, 7, 14, 28, 41, and 84, venous blood was analyzed by the
methods detailed for screening. Additionally, a noninvasive oximeter
(Masimo set; Masimo Corp., CA) recorded peripheral blood oxy- and
methemoglobin (metHb) levels. Subjects were queried for adverse events
during the same clinical visits. Blood for routine blood films was collected
on days 3, 7, 14, 21, 28, 35, 41, 56, 63, 70, 84, 126, 140, 180, and 365. All
visits to the clinic with illness prompted blood film examination, regard-
less of the day of study.
A positive diagnosis of malaria confirmed by a second microscopist
prompted immediate rescue therapy according to national treatment
guidelines (8), except that a 0.5-mg/kg daily primaquine dose was applied
(in lieu of 0.25 mg/kg). Blots of blood were collected onto Whatman FTA
Classic card filter paper when subjects had malaria. DNA extracted from
these was analyzed using a multiplex sphere-based PCR assay (26).
Statistical analysis. Data were double entered into an Access data-
base and validated using EpiInfo (version 3.5.1) software. The statis-
tical analysis used the Stata (version 11) program. Descriptive statistics
were performed to determine the proportions for categorical data and
the summary statistics for continuous data. Chi-square and Fisher’s
exact tests compared proportions. The Kruskal-Wallis test was used
for nonparametric comparisons. The primary endpoint was the per-
cent therapeutic efficacy of the treatment groups, calculated using the
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incidence density (ID) of recurrent P. vivax, as follows: [(IDAS IDQN
or IDDHA-PP)/IDAS]  100.
The 95% confidence interval (CI) for the estimate was calculated from
the binomial distribution. Incidence density was the number of P. vivax
recurrences divided by the sum of person-years at risk at the end of the
study. Cumulative incidence was estimated using life table calculations with
application of weekly intervals (27). The study was powered for a primary
assessment of the noninferiority of primaquine against relapse when part-
nered with QN versus DHA-PP for radical cure. Per protocol, this required 60
subjects per treatment arm, a number not realized in recruitment. We thus
defaulted to the secondary objective, precision in individual estimates of PQ
efficacy in each treatment arm, as reported here.
RESULTS
Screening and enrollment. Figure 1 summarizes the patient and
subject flow during the study. Malaria occurred in 152 soldiers,
with 9 cases being P. falciparum malaria. Among 143 eligible pa-
tients diagnosed with acute P. vivax infection, 27 were not en-
rolled: 4 were G6PD deficient, 6 were clinically unfit (because of
recent antimalarial therapy [n  2], elevated liver enzymes [n 
2], or acute hepatitis [n  2]), 6 refused consent, 2 had planned
absences, and 9 declined to specify a reason. These 36 patients
were promptly treated according to national guidelines and mon-
itored until they fully recovered. One hundred sixteen soldiers
with vivax malaria were randomized to AS (n  41), QNPQ
(n  39), or DHA-PPPQ (n  36). One subject assigned to
QNPQ withdrew informed consent after enrollment but prior
to initiating treatment, leaving 38 subjects in this arm. PCR diag-
nostics later affirmed the enrollment diagnosis of P. vivax infec-
tion in 114 subjects; 2 discordant PCR diagnoses were positive for
Plasmodium falciparum and Plasmodium malariae, respectively.
Both of those subjects had been assigned to QNPQ and were
excluded from analysis, leaving 36 evaluable subjects in that arm.
In all, 113 subjects were evaluable at the close of the study.
Figure 2 illustrates the timing and means of case detection dur-
ing the period of enrollment (30 November 2010 to 26 April
2011). The first mass screening of soldiers for asymptomatic ma-
laria occurred during the first 2 weeks of subject recruitment, dur-
ing which 45 soldiers were found to be positive for vivax malaria
by screening and 3 soldiers reported to the clinic complaining of
illness. Despite further mass blood film screening up to week 21 of
recruitment, no soldiers were found to be positive. The remaining
88 soldiers found to be positive all came to the study clinic com-
plaining of illness throughout the recruitment period.
Table 1 lists the baseline demographic, laboratory, and clinical
features among the treatment groups. Young men (mean age, 27
to 28 years; age range, 22 to 42 years; P 0.89) of similar weights
(mean weight, 65 to 67 kg; weight range, 52 to 90 kg; P  0.90)
having similar parasitemias (median, 1,304 to 2,264 parasites/l
blood; range, 32 to 15,248 parasites/l blood;P 0.83) composed
the study population. Fever (37.5°C) occurred in 17% to 33% of
subjects among the groups (P 0.17). No significant differences
in any mean vital sign or laboratory measurement of blood ap-
peared. The incidence of complaints of illness among the groups
at enrollment was essentially similar, with headache (0.7 com-
plaint/person-day), fever (0.6 complaint/person-day), muscle
ache (0.4 complaint/person-day), nausea (0.2 complaint/per-
son-day), cough (0.05 complaint/person-day), and vomiting
(0.05 complaint/person-day) being the dominant complaints.
Tolerability and safety. The dominant complaints of illness
and many minority complaints fell sharply during treatment and
resolved by the end of treatment. Only two exceptions occurred:
no one complained of tinnitus or hearing loss at enrollment, but
individuals in the QNPQ group did so during treatment (0.2
and 0.1 complaint/person-day, respectively). Four subjects were
hospitalized during the study and were recorded as having serious
adverse events, but the DSMB considered none to be related to
either acute malaria or study drugs (appendicitis, colitis, and
trauma [n 2]).
Most laboratory findings during the first 3 months of study
among the groups remained within normal ranges before, during,
and after treatment. These included white blood cell counts; per-
cent monocytes; red blood cell count; mean corpuscular volume;
mean corpuscular hemoglobin; mean corpuscular hemoglobin
concentration; percent red cell distribution width; and glucose,
urea, creatinine, serum glutamic oxalacetic transaminase, serum
glutamic pyruvic transaminase, total protein, albumin, alkaline
phosphatase, gamma glutathione, lactate dehydrogenase, creatine
FIG 1 Screening, enrollment, randomization, and follow-up of subject patients.
FIG 2 Case detection means and timing during subject recruitment in the
study. Active case detection (ACD) versus passive case detection (PCD) find-
ings of acute vivax malaria among soldiers reporting to the study clinic com-
plaining of illness are illustrated.
Sutanto et al.
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kinase, sodium, potassium, and chloride concentrations. Some
values did change (Fig. 3), however: initially depressed lympho-
cytes and platelets (approximately 20% and 180,000/l, respec-
tively) recovered to normal within 3 to 7 days (approximately 35%
and 200,000/l, respectively) of treatment in all groups, and ele-
vated granulocytes and total bilirubin (approximately 75% and 2
mg/dl, respectively) returned to normal levels (approximately
60% and 1 mg/dl, respectively) within 3 days of treatment. All
groups showed a slight drop in mean hemoglobin concentration
(0.5 g/dl to approximately 13 to 14 g/dl) within 3 days of starting
treatment, followed by incremental increases up to day 84 (to
approximately 15 g/dl). One soldier randomized to DHA-PP had
just 8.3 g/dl hemoglobin at enrollment, and his recovery to normal
levels may be seen in Fig. 3 as the lowest outlier data point up to
day 41. This borderline anemic soldier did not experience a post-
therapy drop in hemoglobin but saw steady increases on days 3, 7,
14, 41, and 84.
Figure 4 illustrates metHb levels sharply rising among groups
dosed with PQ, peaking at about day 7 postpatency and remaining
at that level until the cessation of dosing a week later. The mean
metHb level peaked at approximately 6%, with interquartile
ranges not exceeding 10%. A single measurement in one subject
(QNPQ group) was 17% (not shown in Fig. 3). metHb returned
to normal levels in all subjects within 2 weeks of completing PQ.
Therapeutic response. All except 3 subjects (1 in the QNPQ
group and 2 in the DHA-PP group) were negative for blood-stage
parasites within 3 days, and none of these subjects later had a
recurrence. No subjects were positive at day 7 or day 14. The
earliest recurrence appeared at day 17 in a subject in the AS group,
and he was followed in rapid succession by most other subjects in
the AS arm; 32 of 41 (78%) had recurrences, and 25 of these 32
(78%) appeared on or before day 28 postpatency. The seven other
recurrences appeared between days 29 and 163; day 21 was the
median day of recurrence in this group. All recurrences in all three
treatment arms were identified by microscopy and confirmed
with PCR diagnostics to be P. vivax monoinfections. All 41 recur-
rences among the subjects in the three arms were classified as
relapses (see Discussion).
Figure 5 illustrates the cumulative incidence of relapse among
treatment arms at weekly intervals. Among QNPQ subjects,
seven relapses occurred between days 36 and 194. Two subjects
that received DHA-PPPQ relapsed on days 82 and 126. The nine
study subjects who relapsed following primaquine therapy were
not heavier than subjects given successful primaquine therapy
(P  0.6). All relapses were treated with DHA-PPPQ as per
study treatment, and none of these relapsed again up to the closure
of the study and withdrawal of the study team from Lumajang in
May 2012. In November 2012, the battalion medical team at
Lumajang reported no cases of malaria since closure of the study.
Table 2 summarizes estimates of the relapse-controlled thera-
peutic efficacy of PQ on the basis of the incidence density of re-
current parasitemia. These were 0.226 and 0.058 relapses/person-
year for QNPQ and DHA-PPPQ, respectively. The
denominator for the estimate of PQ efficacy was the incidence
density of relapse among subjects receiving AS alone, i.e., 2.71
relapses/person-year. The efficacy of QNPQ against relapse was
92% (95% CI  81 to 96%), and for DHA-PPPQ it was 98%
(95% CI  91 to 99%). Efficacy calculated by cumulative inci-
dence is also shown in Table 2: 75% (95% CI  52 to 87%) for
QNPQ and 93% (95% CI 72 to 98%) for DHA-PPPQ.
DISCUSSION
This study found good safety, tolerability, and efficacy of PQ
against relapse in G6PD-normal men when administered after
DHA-PP for acute vivax malaria. The efficacy of PQ (by incidence
density) with QN was not significantly lower than that of PQ with
DHA-PP (P 0.19), but QN therapy came with side effects typical
of cinchonism, along with less convenient dosing than DHA-PP.
These findings show excellent PQ efficacy when partnered with
this new artemisinin-combined therapy (ACT) (28) for radical
cure of vivax malaria.
The relatively low estimate of efficacy of QNPQ by cumula-
tive incidence (75%) versus incidence density (92%) calculations
derives from the effect of mathematical management of the re-
spective denominators and the relatively long period of follow-up.
Similar effects have been observed in trials of malaria chemopro-
phylaxis also involving prolonged follow-up (22, 29). The primary
distinction between the two approaches is a denominator that
does not increase as time passes versus one that does, i.e., cumu-
lative incidence versus incidence density, respectively. As more
time passes, the difference expands. The mathematics of this phe-
nomenon have been explained (30, 31). Like those statisticians, we
consider incidence density to be the preferred analytical approach
in estimating primaquine efficacy because, like trials of chemo-
prophylaxis, inclusion of person-time at risk offers more mean-
ingful estimates of efficacy against intrinsically prolonged events
TABLE 1 Characteristics of subject patients among assigned treatment
arms at enrollment
Characteristic
Result by treatment assignment
P
valueAS QNPQ DHA-PPPQ
No. (%) of subjects 41 (35.3) 39 (33.6) 36 (31.0) 0.78
Age (yr)
Mean 27.7 27.1 27.8 0.89
Range 21.5–38.8 22.1–31.5 23.6–42.1
Wt (kg)
Mean 66.5 65.4 65.0 0.90
Range 52–90 52–90 55–78
Mean tympanic temp (°C) 36.7 36.7 36.9 0.67
No. (%) of febrile patients 7 (17.1) 7 (18.0) 12 (33.3) 0.17
Parasite count (no. of
parasites/l blood)
Median 1,408 1,304 2,264 0.83
Range 32–15,248 32–8,560 48–10,112
Mean hemoglobin concn
(g/dl)
14.2 14.0 13.5 0.06
Mean blood glucose
concn (mg/dl)
108 107 110 0.82
Mean total bilirubin level
(mg/dl)
1.95 1.69 1.97 0.23
Mean platelet count (no.
of platelets [103]/ml)
167 162 156 0.64
Mean white blood cell
count (no. of
cells/l)
7,700 7,500 7,700 0.83
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like relapse. The informative visual representation of timing of
relapse represents the primary utility of the cumulative incidence
analysis in this study.
Evidence of Lumajang being free of malaria transmission per-
mitted assignment of a very low probability to reinfection con-
founding in this study. Recrudescence must likewise be carefully
considered. If AS, QN, or DHA-PP failed to kill all asexual blood
stages, recrudescence would confound estimates of PQ efficacy
against hypnozoites. However, late recurrences (Fig. 5) and good
evidence of efficacy for the applied regimens of QN and DHA-PP
(9, 10, 32–34) also render recrudescence an improbable con-
founder. The rapid recurrences following AS therapy warrant
greater caution, but evidence supports these being classified as
relapses. First, the doses of AS applied have been demonstrated to
be completely efficacious against asexual blood stages of P. vivax
(32, 35, 36). Second, the rapidity and risk of relapse seen in the AS
group (Fig. 5) precisely mirrored the natural rate of relapse for the
Chesson strain of P. vivax (37) from an American soldier infected
in New Guinea in 1944 (38). This high rate of relapse also occurred
among Thai patients observed as inpatients in a hospital in Bang-
kok, Thailand (32). The Chesson strain from New Guinea, where
the infections treated in this study were acquired, has historically
been considered PQ tolerant (7, 39) but typically responsive to the
420-mg total dose delivered in this study (14).
Alving et al. (11) demonstrated that QN or CQ, despite having
no effect on relapse without PQ, strongly potentiated the hypno-
zoitocidal activity of PQ when administered concurrently. Recent
findings of the activity of a PQ-like drug against relapse of Plas-
modium cynomolgi in rhesus macaques also point to potentiation:
the dose minimally effective against relapse decreased 10-fold
FIG 3 Summary of blood laboratory findings with changes during the course of treatment and convalescence to day 84 showing the median (horizontal lines),
interquartile range (boxes), 1.5-fold the quartile range (vertical lines), and outlying observations (points).
Sutanto et al.
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when administered with blood schizontocides (40). DHA-PP may
also have potentiated PQ against relapse, despite a 25-day interval
before PQ administration. If potentiation occurred, PP seems to
be the agent more likely responsible because DHA is rapidly ex-
creted (elimination half-life,1 h), whereas the elimination half-
life of PP is 3 to 4 weeks (41). PP thus would have been present
through PQ dosing in weeks 5 and 6, but the relationship between
those levels and the possible potentiation of the therapeutic activ-
ity of PQ remains unknown.
The timing of post-PQ relapse demonstrates an important fac-
tor in estimating the efficacy of PQ, especially in the context of a
rapidly versus a slowly eliminated blood schizontocide. Despite
the high risk of relapse by day 28 (as in the AS group; Fig. 5), PQ
failure (relapse) did not occur during that period but occurred
later and continued up to 28 weeks. Similarly, subjects with can-
didate 8-aminoquinoline failures against Chesson strain relapse in
experimental challenge trials also relapsed later than 28 days (42).
The therapeutic efficacy of PQ may not be ascertained with a fol-
FIG 5 Cumulative incidence of recurrent parasitemia among treatment
groups over 1 year of observation. The first relapse occurred on day 17 post-
patency (AS), and the last occurred on day 194 (QNPQ).
FIG 4 metHb levels (percent for each y axis) among subjects showing the median (horizontal lines), interquartile range (boxes), 1.5-fold the quartile range
(vertical lines), and outlying observations (points) relative to the days of daily primaquine dosing (gray boxes).
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low-up of less than 3 months even for the rapidly relapsing strains
from Southeast Asia and Oceania; subjects infected with strains
having much longer relapse intervals (6) would likely require 8 to
12 months of follow-up. In the current study, no first relapses
occurred in the latter half of the 12-month observation period; a
6-month follow up may suffice in the future.
Suppression of early relapse by slowly excreted blood schizon-
tocides should also be considered in the timing of relapse in trials
of PQ efficacy. In this study, the QN treatment arm demonstrated
PQ killing of the hypnozoites responsible for the early relapses
evident in the AS treatment arm (Fig. 5). Conversely, in the
DHA-PP treatment arm, many relapses would have occurred be-
fore the first dose of PQ on day 28, but these emergent blood stages
were almost certainly killed by the therapeutic levels of the PP
blood schizontocide lingering for about 1 month (9). It is doubt-
ful, however, that such activity explains the apparently good effi-
cacy of PQ against hypnozoites with this partner drug; multiple
relapses are the rule for strains ofP. vivax from New Guinea (6). In
earlier studies (43), a 55% relapse rate was detected between days
38 and 63 posttreatment with slowly eliminated CQ, whereas the
relapse rate from days 17 to 28 was 60% among subjects treated
with rapidly eliminated QN (no PQ either group). This slight dif-
ference reflects the very high probability of relapse, despite sup-
pression of the earliest relapses by a slowly eliminated blood schi-
zontocide.
All of the acute vivax malaria cases treated in this study were
very likely relapses rather than primary attacks. Most subjects re-
cruited were initially negative for malaria at mass screening and
only later developed acute vivax malaria (Fig. 2). Even the 45 sol-
diers found to be positive in the first mass screening within 2
weeks of commencing enrollment were almost certainly not expe-
riencing primary attacks: at that point they had not been exposed
to biting infectious anopheline mosquitoes for over a month. All
of these soldiers probably experienced one or more primary at-
tacks during their 1 year of duties in the high-transmission area
(21, 22). Chemoprophylaxis is not medical doctrine of the Indo-
nesian army, and it is not routinely practiced. The battalion med-
ical team reported treating many soldiers while deployed, but re-
cords were not maintained. Soldiers were treated with stocks of
various ACTs provided by the army health authorities in the re-
gion. At no time did the army medical team administer prima-
quine therapy for acute malaria in the field, as they lacked a capac-
ity for screening for G6PD deficiency and feared causing serious
harm. First exposure to primaquine by the infections acquired by
the study subjects occurred with the therapies administered in this
study.
The findings of this study provide clinical evidence of the good
safety, tolerability, and efficacy of DHA-PPPQ for radical cure
of vivax malaria. This option may be applied in the face of emerg-
ing CQ-resistant P. vivax. The safety of the more convenient con-
current administration of DHA-PPPQ remains to be evaluated.
Despite this significant progress in chemotherapeutics for vivax
malaria, the problem of PQ toxicity in G6PD-deficient patients
and the prohibition of its use in pregnant women and very young
children remain very significant obstacles to effective PQ therapy
against relapse in zones of endemicity. Practical point-of-care di-
agnostics for G6PD deficiency constitute an urgent requirement
in support of broader application of this therapy against relapse in
malaria control and elimination. As the data in Fig. 5 starkly illus-
trate, failure to attack the hypnozoite reservoir in zones of ende-
micity poses a conspicuously serious threat to the health of several
billion people.
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